Perspectives and challenges in regenerative medicine using plasma rich in growth factors

Anitua, Eduardo; Alkhraisat, Mohammad Hamdan; Orive, Gorka

doi:10.1016/j.jconrel.2011.07.004

Cited by 178 publications

(142 citation statements)

References 121 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…PRGF is a source of growth factors including hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), transforming growth factor beta-1 (TGFβ1), and vascular endothelial growth factor (VEGF), many of which are known to stimulate cell proliferation, osteogenesis, and cell survival [14,26]. Our results indicate a cytoprotective effect of PRGF in cells exposed to ZA.…”

Section: Discussionmentioning

confidence: 71%

PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 71%

PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Existem vários fatores de crescimento que são liberados a partir dos α-grânulos presentes nas plaquetas, sendo alguns dos principais disponíveis no PRP o transformante beta 1 (TGF-β1), derivado das plaquetas (PDGF), fibroblás-tico básico (bFGF), epitelial (EGF) e o endotelial vascular (VEGF) (Anitua et al 2012, Boswell et al 2012, Renzi et al 2013. Considera-se que a liberação dos fatores de crescimento pelas plaquetas contidas no PRP pode favorecer a reparação das lesões, e possibilitar o mais rápido retorno à funcionalidade, possivelmente por estimular a neovascularização, que melhora o suprimento sanguíneo e disponibiliza nutrientes necessários à regeneração tecidual.…”

Section: Introductionunclassified

Quantificação de fatores de crescimento na pele de equinos tratada com plasma rico em plaquetas

et al. 2014

View full text Add to dashboard Cite

ABSTRACT.-Souza M.V., Pinto J.O., Costa M.M., Santos E.C., Garcia S.L.R. & Oliveira L.L. 2014.[Quantification of growth factors in horse skin treated with platelet-rich plasma.] Quantificação de fatores de crescimento na pele de equinos tratada com plasma rico em plaquetas. Pesquisa Veterinária Brasileira 34(6):599-612. Departamento de Veterinária, Universidade Federal de Viçosa, Campus Universitário s/n, Viçosa, MG 36570-000, Brazil. E-mail: msouza@ufv.br Platelet-rich plasma (PRP) is a product derived from total blood centrifugation, rich in bioactive factors, such as growth factors. Despite largely used in healing processes, there is a controversy whether the therapy is effective in promoting skin healing. The objective of this study was to quantify and compare the concentrations of the factors TGF-β1 and PDGF-BB in PRP, blood plasma and skin, at different phases of the healing process of skin treated or not with PRP. Seven healthy crossbred 16 to 17-year-old geldings (16.14±0.63) were used. Three quadrangular-shaped lesions (6.25cm 2 ) were surgically induced into the right and left gluteal regions of all animals. Twelve hours after induction of the wounds, 0.5mL of the PRP was administered in each of the four edges of the wound in one of the gluteal regions (Treated group = TG) randomly chosen. The contralateral region was used as control (CG). The wounds were submitted to daily cleaning with Milli-Q water, and samples were obtained with a 6mm diameter biopsy Punch. Six skin biopsies were obtained, the first carried out immediately after the production of the wound (T0), and the others 1 (T1), 2 (T2), 7 (T3), and 14 (T4) days after the lesion was induced. The sixth biopsy (T5) was obtained after complete healing of the skin, which occurred at about day 37 (36.85±7.45, CG; 38.85±6.46, TG). EDTA blood samples were also obtained, at all the times mentioned. Quantification of TGF-β1 and PDGF-BB growth factors on the skin, PRP, and blood plasma was carried out by the ELISA technique. Data were statistically analyzed by the t test, Pearson correlation and regression, at a significance level of 5%. No difference was found between the groups in the values of the two growth factors measured on the skin, at the different times. Also, no correlation was found between the amount of growth factors present in the skin and plasma. On the other hand, a positive correlation was observed between PRP and skin in the treated group, for the growth factors TGF-β1 (r=0.31) and PDGF-BB (r=0.38), as well as between both growth factors present in PRP (r=0.81). Considering the growth factor concentrations at T0, the highest skin values (p<0.05) of TGF-β1, in both groups, occurred at T3 and T5. Higher values (p<0.05) of PDGF-BB occurred at T4 (TG) and T5 (CG). No plasma changes occurred at the concentration of these factors in relation to T0, suggest-1 Recebido em 5 de outubro de 2013.Aceito para publicação em 5 de junho de 2014.

show abstract

“…After platelet activation, a 3-dimensional and biocompatible fibrin scaffold is developed, and at the same time a wide content in growth factors and proteins are released to the local environment in a progressive manner, thus stimulating wound healing and tissue regeneration [16] . Several studies have described the tissue regeneration potential of PRGF eye drops in the ophthalmological field [32][33][34] .…”

Section: Discussionmentioning

confidence: 99%

“…PRGF (plasma rich in growth factors) is an autologous technology which involves the elaboration and use of platelet-enriched plasma that allows the formation of a biodegradable fibrin scaffold and the release of a pool of biologically active proteins that promote tissue regeneration [16,17] . PRGF formulations have other important biological features including antimicrobial, anti-inflammatory and antifibrotic properties necessary to achieve successful tissue regeneration [18][19][20] .…”

mentioning

confidence: 99%

Subconjunctival PRGF Fibrin Membrane as an Adjuvant to Nonpenetrating Deep Sclerectomy: A 2-Year Pilot Study

Rodríguez-Agirretxe

Freire²,

Muruzábal

et al. 2017

Ophthalmic Res

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the potential role of the autologous PRGF (plasma rich in growth factors) fibrin membrane in tissue regeneration after glaucoma filtering surgery. Materials and Methods: Ten patients with medically uncontrolled primary open-angle glaucoma underwent nonpenetrating deep sclerectomy and were treated with PRGF fibrin membrane as adjuvant. Intraocular pressure reduction was the primary outcome. This variable was measured preoperatively and also at each follow-up visit. Secondary outcomes included the number of antiglaucoma medications, anterior segment optical coherence tomography bleb examination, photographic bleb evaluation, and subjective clinical symptomatology evaluation. Results: The surgical technique showed a significant reduction (p < 0.05) in intraocular pressure in relation to preoperative values at each time of the study, decreasing from 23.3 ± 6.4 to 15.2 ± 4.6 mm Hg at 2 years. Furthermore, the number of antiglaucoma medications consumed showed a significant reduction at the end point of the study compared with the preoperative situation. Optical coherence tomography and photographic filtering bleb variables experienced a progressive reduction during the follow-up. Subjective symptoms showed a reduction from 8.3 ± 4.5 to 4.2 ± 5.3 at 2 years. Conclusions: PRGF-Endoret treatment could promote ocular surface regeneration after glaucoma surgery, enhancing the surgery success rates and reducing the need for postoperative medications. It is important to highlight that this is a preliminary study and some large clinical studies are necessary to verify these results.

show abstract

Perspectives and challenges in regenerative medicine using plasma rich in growth factors

Cited by 178 publications

References 121 publications

PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells

PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells

Quantificação de fatores de crescimento na pele de equinos tratada com plasma rico em plaquetas

Subconjunctival PRGF Fibrin Membrane as an Adjuvant to Nonpenetrating Deep Sclerectomy: A 2-Year Pilot Study

Contact Info

Product

Resources

About